Page last updated: 2024-11-04

penicillin v

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Penicillin V is a penicillin-type antibiotic that is active against a wide range of gram-positive bacteria. It is a semisynthetic derivative of penicillin G, modified to improve its oral bioavailability. Penicillin V is absorbed from the gastrointestinal tract and reaches therapeutic concentrations in the blood. It is primarily used to treat infections caused by susceptible strains of Streptococcus, Staphylococcus, and other gram-positive bacteria. The importance of penicillin V lies in its effectiveness in treating a variety of infections, its relative safety, and its ability to be administered orally. Penicillin V is commonly studied to understand its pharmacokinetic properties, its mechanism of action, and its resistance patterns. Research is also conducted to explore its potential use in combination therapy with other antibiotics to enhance its efficacy and to develop new derivatives with improved properties.'

Penicillin V: A broad-spectrum penicillin antibiotic used orally in the treatment of mild to moderate infections by susceptible gram-positive organisms. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

phenoxymethylpenicillin : A penicillin compound having a 6beta-(phenoxyacetyl)amino side-chain. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6869
CHEMBL ID615
CHEBI ID27446
CHEBI ID53706
SCHEMBL ID49223
SCHEMBL ID22099709
MeSH IDM0016142
PubMed CID5484463
CHEMBL ID1197556
CHEBI ID38002
CHEBI ID37994
SCHEMBL ID737002
SCHEMBL ID13619260
MeSH IDM0016142
PubMed CID4731
CHEMBL ID1711169
CHEBI ID94454
SCHEMBL ID9706988
MeSH IDM0016142

Synonyms (222)

Synonym
acipen-v
BRD-K43966364-237-02-2
(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenoxyacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(phenoxyacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DIVK1C_000779
KBIO1_000779
(2s,5r,6r)-3,3-dimethyl-7-oxo-6-{[(phenyloxy)acetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
SPECTRUM_001007
CHEBI:27446 ,
6-phenoxyacetamidopenicillanic acid
penicillin phenoxymethyl
fenospen
v-cillin
phenoxymethylpenicillin
2,2-dimethyl-6beta-[(phenoxyacetyl)amino]penam-3alpha-carboxylic acid
phenoxymethylpenicilline
phenoxymethylpenicillinum
pv
phenoxymethylenepenicillinic acid
3,3-dimethyl-6beta-[(phenoxyacetyl)amino]penam-2alpha-carboxylic acid (pin)
oracillin
phenoxomethylpenicillin
fenoximetilpenicilina
D05411
phenoxymethylpenicillin (inn)
penicillin v (usp)
SPECTRUM5_001409
v-cillin (tn)
IDI1_000779
BSPBIO_002185
PNV ,
(2s,5r,6r)-3,3-dimethyl-7-oxo-6-(2-phenoxyacetamido)-4-thia-1- azabicyclo(3.2.0)heptane-2-carboxylic acid
AB00514745
fenoximetilpenicilina [inn-spanish]
phenoxymethylpenicillinic acid
penicillanic acid, 6-phenoxyacetamido-
v-cil
phenomycilline
calcipen
vebecillin
4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-((phenoxyacetyl)amino)-, (2s-(2alpha,5alpha,6beta))-
penicillin v [usan]
fenossimetilpenicillina [dcit]
4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-(2-phenoxyacetamido)-
phenoxymethylpenicillinum [inn-latin]
meropenin
eskacillin v
einecs 201-722-0
pen-v
phenoxymethylpenicilline [inn-french]
crystapen v
eskacillian v
phenoximethylpenicillinum
v-cylina
v-cyline
hsdb 6314
3,3-dimethyl-7-oxo-6-((phenyloxyacetyl)amino)-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid
compocillin v
ccris 752
pen-oral
rocilin
(2s,5r,6r)-3,3-dimethyl-7-oxo-6-(2-phenoxyacetamido)-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid
stabicillin
fenoxymethylpenicillin
v-tablopen
fenacilin
apopen
p-mega-tablinen
distaquaine v
phenocillin
brn 0096259
phenopenicillin
acipen v
oratren
penicillin, phenoxymethyl
ospen
C08126
penicillin v
87-08-1
DB00417
phenoxymethyl penicillin
KBIO2_001487
KBIO2_006623
KBIOGR_000944
KBIOSS_001487
KBIO3_001685
KBIO2_004055
SPECTRUM3_000543
SPECTRUM2_000495
SPECTRUM4_000472
NINDS_000779
SPBIO_000389
MLS001304105
smr000539431
CHEMBL615
CHEBI:53706 ,
phenoxomethylpenicillanyl
phenoxymethylpenicillanyl
phenoxymethylpenicillinic acid potassium salt
fenossimetilpenicillina
AKOS015969737
bdbm50370584
4-27-00-05884 (beilstein handbook reference)
4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-((phenoxyacetyl)amino)-, (2s,5r,6r)-
z61i075u2w ,
phenoxymethylpenicillin [inn]
unii-z61i075u2w
penicillin v [usan:usp]
(2s,5r,6r)-3,3-dimethyl-7-oxo-6-(2-phenoxyacetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
penicillin v [hsdb]
penicillin v [usp-rs]
phenoxymethylpenicillin [who-dd]
phenoxymethylpenicillinum [who-ip latin]
phenoxymethylpenicillin [who-ip]
phenoxymethylpenicillin [mart.]
penicillin v [orange book]
penicillin v [mi]
penicillin v [usp monograph]
phenoxymethylpenicillin [ep monograph]
EPITOPE ID:116056
EPITOPE ID:115011
SCHEMBL49223
6beta-phenoxyacetamido-2,2-dimethylpenam-3alpha-carboxylic acid
BPLBGHOLXOTWMN-MBNYWOFBSA-N
W-109316
phenoxymethylpenicillin, antibiotic for culture media use only
DTXSID3023429 ,
penicillin v, united states pharmacopeia (usp) reference standard
phenoxymethylpenicillin, european pharmacopoeia (ep) reference standard
SBI-0051477.P003
Q422215
BRD-K43966364-237-03-0
penicillin-v-potassium
pc pen vk
gtpl10920
GLXC-25717
penicillinv
SCHEMBL22099709
phenoxymethylpenicillin 100 microg/ml in acetonitrile
phenoxymethyl penicillinic acid*free acid
phenoxymethylpenicillin for system suitability
EN300-19735891
CS-0013728
HY-B0975A
6-(phenoxyacetamido)penicillanic acid
dtxcid303429
penicillin v (usan:usp)
penicillin v (usp-rs)
(2s,5r,6r)-3,3-dimethyl-7-oxo-6-((phenoxyacetyl)amino)-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid
fenoximetilpenicilina (inn-spanish)
3,3-dimethyl-6beta-((phenoxyacetyl)amino)penam-2alpha-carboxylic acid (pin)
phenoxymethylpenicillin (mart.)
2,2-dimethyl-6beta-((phenoxyacetyl)amino)penam-3alpha-carboxylic acid
penicillin, phenoxymethyl-
phenoxymethylpenicilline (inn-french)
4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-((phenoxyacetyl)amino)-, (2s-(2alpha,5alpha,6.beta)).-
phenospen
pen-vee-oral
j01ce02
phenoxymethylpenicillinum (inn-latin)
penicillin v (usp monograph)
phenoxymethylpenicillin (ep monograph)
MLS000532635 ,
smr000137574
NCI60_042174
CBDIVE_000769
20766-49-8
1-ethyl-2-{[1-ethylquinolin-2(1h)-ylidene]methyl}quinolinium
(e)-1,1'-diethyl-2,2'-cyanine
1-ethyl-2-[(e)-(1-ethylquinolin-2(1h)-ylidene)methyl]quinolinium
CHEBI:38002
CHEBI:37994 ,
STK396423
(2e)-1-ethyl-2-[(1-ethylquinolin-1-ium-2-yl)methylidene]quinoline
AKOS001591661
NCGC00245542-01
CHEMBL1197556 ,
64496-43-1
SCHEMBL737002
(2e)-1-ethyl-2-[(1-ethylquinolin-1-ium-2-yl)methylene]quinoline iodide
SCHEMBL13619260
(2e)-1-ethyl-2-[(1-ethylquinolin-1-ium-2-yl)methylene]quinoline;chloride
cid_5717105
(2e)-1-ethyl-2-[(1-ethyl-2-quinolin-1-iumyl)methylidene]quinoline;chloride
bdbm39687
DTXSID40174835
Q27077008
1-ethyl-2-{[(2e)-1-ethyl-1,2-dihydroquinolin-2-ylidene]methyl}quinolin-1-ium
1-ethyl-2-[(1e)-(1-ethyl-2(1h)-quinolinylidene)methyl]quinolinium
(2z)-1-ethyl-2-[(1-ethylquinolin-1-ium-2-yl)methylidene]quinoline
REGID_FOR_CID_4731
MLS000703719
smr000274084
pen v
oracilline
fenoxypen
3,3-dimethyl-7-oxo-6-[(phenoxyacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
STK177293
OPREA1_658892
OPREA1_777083
AKOS000714928
3,3-dimethyl-7-oxo-6-[(2-phenoxyacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
HMS3259N06
HMS2677L13
CCG-113795
4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-((phenoxyacetyl)amino)-, (2s-(2.alpha.,5.alpha.,6.beta.))-
NC00701
AKOS022003331
BPLBGHOLXOTWMN-UHFFFAOYSA-N
3,3-dimethyl-7-oxo-6-[(phenoxyacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid-, [2s-(2.alpha.,5.alpha.,6.beta.)]-
[2s-(2.alpha.,5.alpha.,6.beta.)]-3,3-dimethyl-7-oxo-6-[(phenoxyacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
orocillin
4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-[(phenoxyacetyl)amino]-, [2s-(2.alpha.,5.alpha.,6.beta.)]-
SCHEMBL9706988
CHEMBL1711169
3,3-dimethyl-7-oxo-6-(2-phenoxyacetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
sr-01000314126
SR-01000314126-1
CHEBI:94454
Q27166319
3,3-dimethyl-7-oxo-6-[(1-oxo-2-phenoxyethyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DTXSID90859140

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"2%) patients in the former and latter groups respectively reporting adverse events."( A double-blind randomized trial comparing the efficacy and safety of a 5-day course of cefotiam hexetil with that of a 10-day course of penicillin V in adult patients with pharyngitis caused by group A beta-haemolytic streptococci.
Bingen, E; Carbon, C; Chatelin, A; Guetat, F; Orvain, J; Rio, Y; Zuck, P, 1995
)
0.29
"In the present study on GABHS pharyngitis in children, a once daily (10-mg/kg), 3-day oral regimen of azithromycin was as clinically effective and as safe as traditional penicillin but appeared inferior in eliminating GABHS from the throat."( Evaluation of the efficacy, safety and toleration of azithromycin vs. penicillin V in the treatment of acute streptococcal pharyngitis in children: results of a multicenter, open comparative study. The Swiss Tonsillopharyngitis Study Group.
Heynen, G; Schaad, UB, 1996
)
0.29
" Adverse events, predominantly gastrointestinal, occurred in 73 (33%) of the azithromycin-treated patients and in 87 (40."( Efficacy and safety of azithromycin versus phenoxymethylpenicillin in the treatment of acute maxillary sinusitis.
Hayle, R; Høivik, HO; Lingaas, E; Odegård, T, 1996
)
0.29

Pharmacokinetics

ExcerptReferenceRelevance
" Based on the pharmacokinetic profiles, it is suggested that 1,200,000 IU benzathine penicillin G given every 4 weeks is an appropriate regimen for preventing the recurrence of rheumatic fever in Thai adults."( Pharmacokinetics of rheumatic fever prophylaxis regimens.
Kobwanthanakun, S; Lertluknithi, R; Pruksachatvuthi, S; Thamlikitkul, V, 1992
)
0.28
"In this study the antimicrobial effects of phenoxymethylpenicillin (PM) and pheneticillin (PE) in vitro and in an experimental animal infection model were compared as well as the pharmacokinetic properties of both drugs in patients."( Comparative pharmacodynamics and clinical pharmacokinetics of phenoxymethylpenicillin and pheneticillin.
Mattie, H; Overbosch, D; van Furth, R, 1985
)
0.27
" This was explained by the fact that also the volume of distribution was decreased in the malnourished group with a net result that the half-life was unchanged."( Malnutrition and pharmacokinetics of penicillin in Ethiopian children.
Bolme, P; Eriksson, M; Paalzow, L; Stintzing, G; Woldemariam, T; Zerihun, G, 1995
)
0.29
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35

Compound-Compound Interactions

Penicillin V (500 mg twice a day) vs placebo given in combination with oral pefloxacin (400 mg twicea day) The recognition and interaction of FEZ-1 from Legionella (FEz-1) with penicillinV(PV) and cefoxitin(CFX) was investigated.

ExcerptReferenceRelevance
"To determine the effect of oral penicillin V combined with a fluoroquinolone (pefloxacin) on the occurrence of fever and streptococcal and other gram-positive coccal bacteremic infections in granulocytopenic patients with cancer."( Reduction of fever and streptococcal bacteremia in granulocytopenic patients with cancer. A trial of oral penicillin V or placebo combined with pefloxacin. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and
, 1994
)
0.29
"Penicillin V (500 mg twice a day) vs placebo given in combination with oral pefloxacin (400 mg twice a day)."( Reduction of fever and streptococcal bacteremia in granulocytopenic patients with cancer. A trial of oral penicillin V or placebo combined with pefloxacin. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and
, 1994
)
0.29
" In the first study (study 1), oxymetazoline administered with a bellows (OXBE) was compared both with a placebo belows (PLBE) as well as with oxymetazoline and placebo administered with a conventional nasal spray (OXSP respective PLSP) in 73 patients."( The efficacy of oxymetazoline administered with a nasal bellows container and combined with oral phenoxymethyl-penicillin in the treatment of acute maxillary sinusitis.
Berglund, R; Stierna, P; Tönnesson, M; Westrin, KM; Wiklund, L, 1994
)
0.29
"The recognition and interaction of FEZ-1 from Legionella (FEZ-1) with penicillin V(PV) and cefoxitin(CFX) were investigated using fluorescence spectra in combination with molecular dynamics simulation (MD)."( Recognition and binding of FEZ-1 from Legionella with penicillin V and cefoxitin by fluorescence spectra in combination with molecular dynamics simulation.
Bai, Y; Bian, L; Dong, X; Ma, X; Shi, P; Xue, P, 2021
)
0.62

Bioavailability

The bioavailability of nine commercial pediatric preparations of penicillin V was tested in a double-blind, cross-over fashion on ten healthy student nurses. Megacillin-oral-Trockensaft was compared with that of another commercially available drug containing the same active substance.

ExcerptReferenceRelevance
"The bioavailability of 11 brands of phenoxymethylpenicillin was investigated in a cross-over-study in healthy volunteers."( [Bioavailability of different brands of phenoxymethylpenicillin (author's transl)].
Grothkopp, J; Malerczyk, V; Simon, C, 1975
)
0.25
" The bioavailability of cefuroxime axetil was low due to being administered in the fasting state."( Comparison of the serum and tissue concentrations of cefuroxime from cefuroxime axetil and phenoxymethylpenicillin in patients undergoing tonsillectomy.
Jetlund, O; Thurmann-Nielsen, E; Walstad, RA, 1991
)
0.28
" It is suggested that, if minimal impairment of bioavailability by ingesta is desired, then the penicillins commonly administered by mouth (amoxycillin, ampicillin, penicillin V, phenethicillin, cloxacillin) should be given to dogs that are fasting."( Effect of ingesta on systemic availability of penicillins administered orally in dogs.
Egerton, JR; Emslie, DR; Martin, IC; Watson, AD, 1986
)
0.27
" The elimination t1/2 of the drug after oral dosing varied between 90 and 110 min, and the oral bioavailability was approximately 30% of the dose."( Pharmacokinetics of phenoxymethyl penicillin (penicillin V) in calves.
Kurtz, B; Soback, S; Ziv, G, 1987
)
0.27
" Bioavailability in mice, rats, dogs, and monkeys was determined after oral or parenteral administration."( Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
Cooper, RD; Counter, FT; Draheim, SE; Eudaly, JA; Johnson, RJ; Kukolja, S; Ott, JL; Pfeil-Doyle, J; Quay, JF; Wright, WE, 1988
)
0.27
" Also the relative bioavailability of the potassium salt was greatest, as indicated by the areas under the serum concentration/time curves (AUC)."( Absorption of phenoxymethylpenicillin from mixtures and tablets in healthy volunteers.
Josefsson, K; Magni, L, 1983
)
0.27
"The bioavailability of Megacillin-oral-Trockensaft (active substance: potassium salt of phenoxymethylpenicillin, penicillin V potassium) was compared with that of another commercially available drug containing the same active substance."( [Bioavailability of penicillin V in aqueous dosage forms].
Hirsch, I; Lintz, W; Osterloh, G; Schmidt-Böthelt, E; Sous, H, 1984
)
0.27
"The absorption rate and serum level curves of two commercial phenoxymethylpenicillin mixture preparations were compared in adult volunteers."( Absorption of penicillin V from mixture formulations. Comparison of potassium and benzathine salts.
Heikinheimo, M; Hovi, T, 1981
)
0.26
" The bioavailability was decreased if penicillin was given to non-fasting individuals."( Malnutrition and pharmacokinetics of penicillin in Ethiopian children.
Bolme, P; Eriksson, M; Paalzow, L; Stintzing, G; Woldemariam, T; Zerihun, G, 1995
)
0.29
" The method has proved to be reliable and was used in bioavailability studies for the development of a new oral penicillin-V formulation."( Determination of penicillin-V in human plasma by high-performance liquid chromatography and solid-phase extraction.
Krauwinkel, WJ; Volkers-Kamermans, NJ, 1996
)
0.29
"Although these findings do not provide sufficient evidence to change current treatment recommendations or public health policy, important questions are raised about currently recommended penicillin doses, about the role of the carrier state, and possibly about adequate bioavailability of intramuscular BPG."( Unexplained reduced microbiological efficacy of intramuscular benzathine penicillin G and of oral penicillin V in eradication of group a streptococci from children with acute pharyngitis.
Johnson, DR; Kaplan, EL, 2001
)
0.31
" The result verified the bioavailability of modified penicillin after the ester bond was cleaved."( Penicillin V-conjugated PEG-PAMAM star polymers.
Lopina, ST; Yang, H, 2003
)
0.32
"The utilization of the membrane transport protein PEPT1 as a drug delivery system is a promising strategy to enhance the oral bioavailability of drugs."( Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1.
Biegel, A; Brandsch, M; Gebauer, S; Hartrodt, B; Neubert, K; Thondorf, I, 2005
)
0.33
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36

Dosage Studied

Azithromycin in a dosage of 10 or 20 mg/kg/day one daily for three days was as safe and effective as penicillin V administered four times daily in the treatment of acute pharyngitis/tonsillitis.

ExcerptRelevanceReference
"Two dosage regimens of penicillin V were compared in 327 patients with mild to moderately severe streptococcal pharyngitis."( Penicillin V therapy for streptococcal pharyngitis: comparison of dosage schedules.
Harris, BA; Spitzer, TQ, 1977
)
0.26
" Although azithromycin has been shown to be effective in the treatment of erythema migrans, further studies will be needed to determine the optimal dosage and duration of therapy."( Erythema migrans: comparison of treatment with azithromycin, doxycycline and phenoxymethylpenicillin.
Cimperman, J; Ruzic, E; Strle, F, 1992
)
0.28
" burgdorferi infection was established in gerbils; a dosage of greater than or equal to 25 mg/kg/day roxithromycin for 10 days eliminated the infection."( Roxithromycin in Lyme borreliosis: discrepant results of an in vitro and in vivo animal susceptibility study and a clinical trial in patients with erythema migrans.
Asbrink, E; Halkier-Sørensen, L; Hansen, K; Hovmark, A; Lebech, AM; Lebech, K; Olsson, E; Olsson, I, 1992
)
0.28
" Recruitment for this dosage group is being continued."( Comparative study of cefetamet pivoxil and penicillin V in the treatment of group A beta-hemolytic streptococcal pharyngitis.
De Boeck, K; Pierard, D; Ramet, J; Vandenberghe, P, 1992
)
0.28
"In relation to compliance problems it was investigated whether phenoxymethylpenicillin dosed 2 or 3 times daily was equally effective in bacterial upper respiratory infections."( Phenoxymethylpenicillin two or three times daily in bacterial upper respiratory tract infections: a blinded, randomized and controlled clinical study.
Arnesen, AR; Fyllingen, G; Rønnevig, J, 1991
)
0.28
"Ospen is a dosage form of phenoxymethylpenicilin."( [Use of ospen (a drug form of phenoxymethylpenicillin) in pediatric practice].
Andreeva, EI; Gordeeva-Markova, AK; Isaeva, LA; Polezhaeva, OL; Uskova, TA, 1991
)
0.28
", either dosed once 30 h before marrow preparation, or dosed twice 48 and 24 h before marrow preparation)."( In vitro and in vivo cytogenetic studies of three beta-lactam antibiotics (penicillin VK, ampicillin and carbenicillin).
Gatehouse, D; Pascoe, S; Stemp, G, 1989
)
0.28
" One hundred four children with pharyngitis and serologically confirmed Group A streptococci were randomly treated with cefaclor or penicillin using a mean dosage of 20 mg/kg/day for 10 days."( Comparison of oral cephalosporins with penicillin therapy for group A streptococcal pharyngitis.
Stillerman, M,
)
0.13
"14 micrograms/ml after dosing at 10, 20 and 40 mg/kg, respectively."( Pharmacokinetics of phenoxymethyl penicillin (penicillin V) in calves.
Kurtz, B; Soback, S; Ziv, G, 1987
)
0.27
" Two children got the same therapy, but in a dosage of 400,000 IU three times a day for 10 days."( Treatment and course of erythema chronicum migrans.
Aberer, E; Neumann, R; Stanek, G, 1987
)
0.27
"A modified spectrophotometric method is recommended for the control of the air condition at pharmaceutical plants manufacturing phenoxymethylpenicillin and its dosage forms."( [Spectrophotometric method of determining phenoxymethylpenicillin in the air].
Churagulova, NK, 1985
)
0.27
"The effectiveness of cephalexin, an oral cephalosporin using a dosage equivalent to available capsular dosage forms, was studied in relation to the effectiveness of phenoxymethyl penicillin and benzathine penicillin in the treatment of 128 patients with beta-hemolytic streptococcal pharyngitis, all but six of whom had group A streptococci isolated from throat cultures."( Use of available dosage forms of cephalexin in clinical comparison with phenoxymethyl penicillin and benzathine penicillin in the treatment of streptococcal pharyngitis in children.
Bacaner, H; Matsen, JM; Siegel, SE; Torstenson, O, 1974
)
0.25
" A study has been made of serum, mixed and parotid salivary levels attained in normal volunteers following oral dosage of 500 mg phenoxymethylpenicillin tablets, 500 mg crushed phenoxymethylpenicillin tablets in capsules, 500 mg ampicillin, 500 mg cloxacillin and 500 mg cephalexin."( Comparison of human serum, parotid and mixed saliva levels of phenoxymethylpenicillin, ampicillin, cloxacillin and cephalexin.
Speirs, CF; Stenhouse, D; Stephen, KW; Wallace, ET, 1971
)
0.25
" On the basis of results obtained with three tablet preparations, they have found that CUT specification may favourably be used, applying appropriate methods of determination, in the case of dosage forms for the better fulfilment of quality requirements."( Application of content uniformity test to tablet preparations.
Darbai, MJ; Hadady, KK; Kovács, I, 1980
)
0.26
"In a randomized, prospective, multicenter study the clinical and bacteriological efficacies of three dosage schedules with two different salts of oral penicillin V suspensions (regimen 1: potassium salt of penicillin V, 50,000 U/kg of body weight per day in three divided doses; regimen 2: benzathine salt of penicillin V, 50,000 U/kg of body weight per day in two divided doses; and regimen 3: benzathine salt of penicillin V, 100,000 U/kg of body weight in two divided doses) for the treatment of streptococcal pharyngitis were evaluated."( Randomized evaluation of benzathine penicillin V twice daily versus potassium penicillin V three times daily in the treatment of group A streptococcal pharyngitis. Pharyngitis Study Group.
Kaufhold, A, 1995
)
0.29
" In the light of modern pharmacological insights, multiple dosing schedules may be desirable in the therapy of GAS tonsillitis."( [Streptococcal tonsillitis: failure of penicillin therapy].
Schønheyder, HC, 1994
)
0.29
"To determine whether the normal regimen of dosage of oral penicillin V is relevant during pregnancy."( The need for adjustment of dosage regimen of penicillin V during pregnancy.
Erkkola, RU; Heikkilä, AM, 1993
)
0.29
"Elimination of penicillin V is enhanced during pregnancy, necessitating either a shorter dosing interval (6-8 hours) or an increased dose with the standard dosing interval."( The need for adjustment of dosage regimen of penicillin V during pregnancy.
Erkkola, RU; Heikkilä, AM, 1993
)
0.29
" Cefetamet pivoxil is a new oral cephalosporin with a twice daily dosage and striking stability against beta-lactamases."( Cefetamet pivoxil in the treatment of pharyngotonsillitis due to group A beta-hemolytic streptococci: preliminary report.
Brighi, L; Gervaix, A; Halpérin, DS; Suter, S, 1995
)
0.29
" As a result of its pharmacokinetic profile azithromycin is unique among these alternative antimicrobials in allowing once daily dosing and shorter duration of treatment."( Evaluation of the efficacy, safety and toleration of azithromycin vs. penicillin V in the treatment of acute streptococcal pharyngitis in children: results of a multicenter, open comparative study. The Swiss Tonsillopharyngitis Study Group.
Heynen, G; Schaad, UB, 1996
)
0.29
" Azithromycin in a dosage of 10 or 20 mg/kg/day one daily for three days was as safe and effective as penicillin V administered four times daily in the treatment of paediatric patients with acute pharyngitis/tonsillitis."( Azithromycin versus penicillin V in the treatment of paediatric patients with acute streptococcal pharyngitis/tonsillitis. Paediatric Azithromycin Study Group.
O'Doherty, B, 1996
)
0.29
"A 10-day course of amoxicillin at a dosage of 40 mg per kilogram per day was compared with conventional (lower dosage) penicillin V therapy in the treatment of culture-proven Group A streptococcal pharyngitis in children 3 to 18 years of age in a prospective, randomized, and single-blinded study."( Randomized, single-blinded comparative study of the efficacy of amoxicillin (40 mg/kg/day) versus standard-dose penicillin V in the treatment of group A streptococcal pharyngitis in children.
Garcia, RE; Goldfarb, J; Gopichand, I; Lampe, JB; Lebrun, L; Medendorp, SV; Sabella, C; Saracusa, C; Williams, GD, 1998
)
0.3
" Group 2 received placebo in a similar dosing schedule."( Antibiotic prophylaxis in orthognathic surgery: a 1-day versus 5-day regimen.
Aiello, GA; Bentley, KC; Head, TW, 1999
)
0.3
"To examine whether penicillin treatment success for group A beta-hemolytic streptococcal tonsillopharyngitis is influenced by patient age, number of days ill prior to initiation of treatment, number of prior episodes, season, total dosage (milligrams per kilogram), and frequency of administration (2 vs 3 times daily)."( Variables influencing penicillin treatment outcome in streptococcal tonsillopharyngitis.
Dragalin, V; Francis, AB; Hoeger, W; Marsocci, SM; Murphy, AM; Pichichero, ME, 1999
)
0.3
" The number of prior episodes within the preceding year, the season, the total daily penicillin dose (range, 8-76 mg/kg), and 2 vs 3 times daily dosing did not significantly alter treatment outcome."( Variables influencing penicillin treatment outcome in streptococcal tonsillopharyngitis.
Dragalin, V; Francis, AB; Hoeger, W; Marsocci, SM; Murphy, AM; Pichichero, ME, 1999
)
0.3
" dosing with long-acting forms of penicillin which had been shown to prevent post-streptococcal sequelae."( Comparison of short-course (5 day) cefuroxime axetil with a standard 10 day oral penicillin V regimen in the treatment of tonsillopharyngitis.
Adam, D; Helmerking, M; Scholz, H, 2000
)
0.31
" This multicenter, randomized, controlled, double-masked study assessed the tolerability and efficacy of 2 dosing regimens of cefdinir in the treatment of pharyngitis due to GABHS."( Comparison of cefdinir and penicillin for the treatment of streptococcal pharyngitis. Cefdinir Pharyngitis Study Group.
Gooch, WM; Henry, D; Keyserling, CH; McCarty, J; Nemeth, MA; Tack, KJ, 1999
)
0.3
" As the novel microphysiometer works under regular cell culture conditions, cells can be repeatedly simulated with drugs to complete dose-response curve within a few hours."( A novel microphysiometer based on MLAPS for drugs screening.
Ping, W; Qingtao, Z; Rong, L; Weimin, Y; Xiaoxiang, Z; Xuesong, Y; Yicong, W, 2001
)
0.31
" These assays are potentially useful to study hydroxyurea metabolism further, develop optimal dosing regimes and monitor compliance with treatment."( The measurement of urinary hydroxyurea in sickle cell anaemia.
Awogbade, M; Dalton, RN; Dick, M; Height, SE; Inusa, B; O'Driscoll, S; Okpala, I; Rees, DC; Thein, SL; Turner, C, 2005
)
0.33
" Over 97% of GPs ranked development of paediatric formulations and clearer dosage information more highly than clinical trials as a means to reducing off-label prescribing."( Off-label prescribing to children: attitudes and experience of general practitioners.
Ekins-Daukes, S; Helms, PJ; McLay, JS; Taylor, MW, 2005
)
0.33
" Severe obese patients need higher dosage of antibiotics."( [Use of antibiotics in colorectal surgery in Denmark].
Frimodt-Møller, N; Jensen, TG; Madsen, H; Pedersen, C; Qvist, N; Salomon, S, 2007
)
0.34
" Regardless of the response to penicillin skin testing, patients received the usual 1-day dosage of penicillin and amoxicillin, on 2 separate occasions."( Skin testing and oral penicillin challenge in patients with a history of remote penicillin allergy.
Confino-Cohen, R; Goldberg, A, 2008
)
0.35
" Despite this there remains little evidence-based literature on what should be prescribed for any given clinical situation, at what dosage and for how long."( The role of phenoxymethylpenicillin, amoxicillin, metronidazole and clindamycin in the management of acute dentoalveolar abscesses--a review.
Ellison, SJ, 2009
)
0.35
" The aim is to optimize drug use and dosing regimens to improve the clinical efficacy."( A randomized controlled study of 5 and 10 days treatment with phenoxymethylpenicillin for pharyngotonsillitis caused by streptococcus group A - a protocol study.
Edlund, C; Giske, CG; Hedin, K; Mölstad, S; Norman, C; Skoog, G; Sundvall, PD, 2016
)
0.43
" Old antimicrobial drugs are often associated with inadequate knowledge on pharmacokinetics and pharmacodynamics and lack of optimized dosing regimens based on randomized controlled clinical trials."( A randomized controlled study of 5 and 10 days treatment with phenoxymethylpenicillin for pharyngotonsillitis caused by streptococcus group A - a protocol study.
Edlund, C; Giske, CG; Hedin, K; Mölstad, S; Norman, C; Skoog, G; Sundvall, PD, 2016
)
0.43
" Participants wore a solid microneedle β-lactam biosensor for up to 6 h while being dosed at steady state with oral phenoxymethylpenicillin (five 500 mg doses every 6 h)."( Microneedle biosensors for real-time, minimally invasive drug monitoring of phenoxymethylpenicillin: a first-in-human evaluation in healthy volunteers.
Bayliss, M; Cass, AEG; Freeman, DME; Georgiou, P; Gilchrist, M; Gowers, SAN; Holmes, AH; Kyriakides, M; Lovering, A; MacGowan, A; O'Hare, D; Rawson, TM; Sharma, S; Wilson, RC, 2019
)
0.51
" Future work will explore microneedle use in patient populations, their role in data generation to inform dosing recommendations, and their incorporation into closed-loop control systems for automated drug delivery."( Microneedle biosensors for real-time, minimally invasive drug monitoring of phenoxymethylpenicillin: a first-in-human evaluation in healthy volunteers.
Bayliss, M; Cass, AEG; Freeman, DME; Georgiou, P; Gilchrist, M; Gowers, SAN; Holmes, AH; Kyriakides, M; Lovering, A; MacGowan, A; O'Hare, D; Rawson, TM; Sharma, S; Wilson, RC, 2019
)
0.51
" By utilizing restricted cubic splines, our current study revealed a potential nonlinear dose-response association between FQ exposure and hypertension risk."( Antibiotics in elderly Chinese population and their relations with hypertension and pulse pressure.
Cao, H; Chen, G; Li, X; Li, Z; Liu, A; Liu, K; Tao, F; Wang, Q; Wang, S; Yang, L; Zhang, D; Zhao, J, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (4)

ClassDescription
penicillinAny member of the group of substituted penams containing two methyl substituents at position 2, a carboxylate substituent at position 3 and a carboxamido group at position 6.
penicillin allergenAny penicillin which causes the onset of an allergic reaction.
1,1'-diethyl-2,2'-cyanine
quinolinesA class of aromatic heterocyclic compounds each of which contains a benzene ring ortho fused to carbons 2 and 3 of a pyridine ring.
penicillinAny member of the group of substituted penams containing two methyl substituents at position 2, a carboxylate substituent at position 3 and a carboxamido group at position 6.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (18)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency25.11890.00798.23321,122.0200AID2546
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency19.95260.631035.7641100.0000AID504339
GLS proteinHomo sapiens (human)Potency8.91250.35487.935539.8107AID624170
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency25.11890.707912.194339.8107AID720542
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency89.12510.707936.904389.1251AID504333
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency39.81070.035520.977089.1251AID504332
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency22.38720.425612.059128.1838AID504891
Guanine nucleotide-binding protein GHomo sapiens (human)Potency11.22021.995325.532750.1187AID624287
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 8Mus musculus (house mouse)IC50 (µMol)48.60003.02003.02003.0200AID1209730
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2IC50 (µMol)50.00000.00022.45859.9600AID1910632
Solute carrier family 15 member 1Homo sapiens (human)Ki21,000.00000.18003.39339.8000AID238858
Solute carrier family 22 member 2Homo sapiens (human)IC50 (µMol)1.13000.40003.10009.7000AID681561
Solute carrier family 22 member 2Homo sapiens (human)Ki0.10000.10001.52203.4000AID681171
Solute carrier family 22 member 1 Homo sapiens (human)IC50 (µMol)0.98000.21005.553710.0000AID681560
Solute carrier family 22 member 1 Homo sapiens (human)Ki3.56500.55004.26507.4600AID679498; AID681146
Solute carrier family 22 member 3Homo sapiens (human)IC50 (µMol)0.09000.09003.72779.5000AID682144
Ribosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)IC50 (µMol)2.70000.00271.62879.9000AID540067
Solute carrier family 22 member 1Rattus norvegicus (Norway rat)Ki0.43000.13002.37856.9000AID681157; AID681376
Solute carrier family 22 member 2Rattus norvegicus (Norway rat)IC50 (µMol)13.80001.00004.446710.0000AID678970
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (59)

Processvia Protein(s)Taxonomy
monoatomic ion transportSolute carrier family 15 member 1Homo sapiens (human)
protein transportSolute carrier family 15 member 1Homo sapiens (human)
peptide transportSolute carrier family 15 member 1Homo sapiens (human)
dipeptide import across plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
tripeptide import across plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
proton transmembrane transportSolute carrier family 15 member 1Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processSolute carrier family 22 member 2Homo sapiens (human)
positive regulation of gene expressionSolute carrier family 22 member 2Homo sapiens (human)
organic cation transportSolute carrier family 22 member 2Homo sapiens (human)
monoatomic cation transportSolute carrier family 22 member 2Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 2Homo sapiens (human)
serotonin transportSolute carrier family 22 member 2Homo sapiens (human)
body fluid secretionSolute carrier family 22 member 2Homo sapiens (human)
organic cation transportSolute carrier family 22 member 2Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 2Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 2Homo sapiens (human)
amine transportSolute carrier family 22 member 2Homo sapiens (human)
putrescine transportSolute carrier family 22 member 2Homo sapiens (human)
spermidine transportSolute carrier family 22 member 2Homo sapiens (human)
acetylcholine transportSolute carrier family 22 member 2Homo sapiens (human)
choline transportSolute carrier family 22 member 2Homo sapiens (human)
dopamine transportSolute carrier family 22 member 2Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 2Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 2Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 2Homo sapiens (human)
histamine transportSolute carrier family 22 member 2Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 2Homo sapiens (human)
histamine uptakeSolute carrier family 22 member 2Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 2Homo sapiens (human)
thiamine transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
amino acid import across plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 2Homo sapiens (human)
L-arginine import across plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
export across plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 2Homo sapiens (human)
L-alpha-amino acid transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
L-arginine transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 2Homo sapiens (human)
xenobiotic transport across blood-brain barrierSolute carrier family 22 member 2Homo sapiens (human)
xenobiotic metabolic processSolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin transportSolute carrier family 22 member 1 Homo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradientSolute carrier family 22 member 1 Homo sapiens (human)
organic cation transportSolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transportSolute carrier family 22 member 1 Homo sapiens (human)
putrescine transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transportSolute carrier family 22 member 1 Homo sapiens (human)
acetylcholine transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine transportSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transportSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 1 Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
metanephric proximal tubule developmentSolute carrier family 22 member 1 Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
monoatomic cation transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
acyl carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
histamine metabolic processSolute carrier family 22 member 3Homo sapiens (human)
organic cation transportSolute carrier family 22 member 3Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 3Homo sapiens (human)
monoatomic ion transportSolute carrier family 22 member 3Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 3Homo sapiens (human)
serotonin transportSolute carrier family 22 member 3Homo sapiens (human)
organic cation transportSolute carrier family 22 member 3Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 3Homo sapiens (human)
organic anion transportSolute carrier family 22 member 3Homo sapiens (human)
monocarboxylic acid transportSolute carrier family 22 member 3Homo sapiens (human)
monoamine transportSolute carrier family 22 member 3Homo sapiens (human)
spermidine transportSolute carrier family 22 member 3Homo sapiens (human)
dopamine transportSolute carrier family 22 member 3Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 3Homo sapiens (human)
regulation of appetiteSolute carrier family 22 member 3Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 3Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 3Homo sapiens (human)
histamine transportSolute carrier family 22 member 3Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 3Homo sapiens (human)
histamine uptakeSolute carrier family 22 member 3Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 3Homo sapiens (human)
epinephrine uptakeSolute carrier family 22 member 3Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 3Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 3Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 3Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 3Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 3Homo sapiens (human)
quinone catabolic processRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (51)

Processvia Protein(s)Taxonomy
organic anion transmembrane transporter activitySolute carrier family 22 member 8Mus musculus (house mouse)
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoestersReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
proton-dependent oligopeptide secondary active transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
peptide:proton symporter activitySolute carrier family 15 member 1Homo sapiens (human)
tripeptide transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
dipeptide transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
amine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
acetylcholine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
L-amino acid transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
choline transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
thiamine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
putrescine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
efflux transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
L-arginine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
acetylcholine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
dopamine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
secondary active organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
putrescine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
identical protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
protein bindingSolute carrier family 22 member 3Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
dihydronicotinamide riboside quinone reductase activityRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
protein bindingRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
zinc ion bindingRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
electron transfer activityRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
oxidoreductase activityRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
oxidoreductase activity, acting on other nitrogenous compounds as donorsRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
chloride ion bindingRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
protein homodimerization activityRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
FAD bindingRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
melatonin bindingRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
resveratrol bindingRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
NAD(P)H dehydrogenase (quinone) activityRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (16)

Processvia Protein(s)Taxonomy
basolateral plasma membraneSolute carrier family 22 member 8Mus musculus (house mouse)
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
brush borderSolute carrier family 15 member 1Homo sapiens (human)
membraneSolute carrier family 15 member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
membraneSolute carrier family 22 member 2Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 2Homo sapiens (human)
presynapseSolute carrier family 22 member 2Homo sapiens (human)
plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
membraneSolute carrier family 22 member 1 Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
lateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
presynapseSolute carrier family 22 member 1 Homo sapiens (human)
nuclear outer membraneSolute carrier family 22 member 3Homo sapiens (human)
plasma membraneSolute carrier family 22 member 3Homo sapiens (human)
endomembrane systemSolute carrier family 22 member 3Homo sapiens (human)
membraneSolute carrier family 22 member 3Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 3Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 3Homo sapiens (human)
mitochondrial membraneSolute carrier family 22 member 3Homo sapiens (human)
neuronal cell bodySolute carrier family 22 member 3Homo sapiens (human)
presynapseSolute carrier family 22 member 3Homo sapiens (human)
nucleoplasmRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
cytosolRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
extracellular exosomeRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
cytosolRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (241)

Assay IDTitleYearJournalArticle
AID575101Antimicrobial activity against Streptococcus pneumoniae serotype 23B assessed as percent susceptible isolates by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID574956Antimicrobial activity against multiple drug resistant Streptococcus pneumoniae serotype 6B by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID528521Antimicrobial activity against penicillin-resistant Streptococcus agalactiae ATCC BAA-611 by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID528530Antimicrobial activity against penicillin-resistant Streptococcus agalactiae B40 by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID1067507Inhibition of Escherichia coli BL21(DE3) PBP2 after 30 mins by SDS-PAGE2014ACS medicinal chemistry letters, Feb-13, Volume: 5, Issue:2
Neutral β-Lactams Inactivate High Molecular Mass Penicillin-Binding Proteins of Class B1, Including PBP2a of MRSA.
AID132394Efficacy against mouse infected ip with C203 strain of Streptococcus pyogenes, administered sc to 19-21-g random sex ICR mice at 1 hr and 5 hr1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID1067508Inhibition of Escherichia coli PBP1a/1b after 30 mins by SDS-PAGE2014ACS medicinal chemistry letters, Feb-13, Volume: 5, Issue:2
Neutral β-Lactams Inactivate High Molecular Mass Penicillin-Binding Proteins of Class B1, Including PBP2a of MRSA.
AID23107Mean plasma levels in rats 1 hr after iv administration of 100 mg/kg of probenecid 5 min prior to test compound1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID131501Effective dose administered orally (po) to 19-21-g random sex ICR mice at 1 hr and 5 hr intervals after intraperitoneal Streptococcus pyogenes1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 2. Expanded structure-activity relationships of 7-(arylacetamido)-3-substituted cephalosporins.
AID560131Activity of recombinant beta-lactamase RTG4 expressed in Escherichia coli TOP10 by nitrocefin hydrolysis assay2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii.
AID23112Mean plasma levels in rats 20 min after iv administration of 100 mg/kg of probenecid 5 min prior to test compound1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID575079Antimicrobial activity against Streptococcus pneumoniae serotype 7F assessed as percent susceptible isolates by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID528528Antimicrobial activity against penicillin-resistant Streptococcus agalactiae B10 by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID232578Ratio of ED50 value evaluated in Streptococcus pneumoniae by po to sc administration1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 2. Expanded structure-activity relationships of 7-(arylacetamido)-3-substituted cephalosporins.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID592681Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
QSAR-based permeability model for drug-like compounds.
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID523274Activity at Escherichia coli isolate 7181 beta-lactamase OXA-7 measured per mg of protein2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Kinetic parameters of efflux of penicillins by the multidrug efflux transporter AcrAB-TolC of Escherichia coli.
AID528522Antimicrobial activity against Streptococcus pneumoniae ATCC 49619 by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID64043In vitro minimal inhibitory concentration (MIC) in brain-heart infusion broth in the presence of hog liver esterase(1:1.5) in Escherichia coli 2661990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporins to carbapenems: 1-oxygenated carbapenems and carbapenams.
AID574955Antimicrobial activity against multiple drug resistant Streptococcus pneumoniae serotype 19F by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID245252Minimum inhibitory concentration against gram positive Bacillus subtilis (MTCC 441) using broth dilution method2005Bioorganic & medicinal chemistry letters, Sep-01, Volume: 15, Issue:17
Synthesis and in vitro study of novel 7-O-acyl derivatives of Oroxylin A as antibacterial agents.
AID575078Antimicrobial activity against Streptococcus pneumoniae serotype 35B assessed as percent susceptible isolates by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID133268Efficacy against mouse infections caused by Staphylococcus aureus measured as Minimum inhibitory concentration1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 2. Expanded structure-activity relationships of 7-(arylacetamido)-3-substituted cephalosporins.
AID25018Compound was evaluated for its hydrolysis at pH 10 expressed as pseudo first order rate constant (K) (micro = 0.5)1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
Synthesis, hydrolysis rates, supercomputer modeling, and antibacterial activity of bicyclic tetrahydropyridazinones.
AID528535Antimicrobial activity against penicillin-resistant Streptococcus agalactiae B513 by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID132260Efficacy against mouse infected ip with 3055 strain of Staphylococcus aureus, administered po to 19-21-g random sex ICR mice at 1 hr and 5 hr1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID575103Antimicrobial activity against Streptococcus pneumoniae serotype 23A assessed as percent susceptible isolates by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID22648dose in urine (24-h urine excretion) in female mongrel dogs after, iv administration of single 15 mg/kg dose1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID245345Minimum inhibitory concentration against gram negative Chromobacterium violaceum (MTCC 2656) using broth dilution method2005Bioorganic & medicinal chemistry letters, Sep-01, Volume: 15, Issue:17
Synthesis and in vitro study of novel 7-O-acyl derivatives of Oroxylin A as antibacterial agents.
AID132261Efficacy against mouse infected ip with 3055 strain of Staphylococcus aureus, administered sc to 19-21-g random sex ICR mice at 1 hr and 5 hr1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID208287Minimum inhibitory concentration against Park strain of Streptococcus pneumoniae1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID719024Antibacterial activity against methicillin-resistant Staphylococcus aureus H 5996/08 assessed as growth inhibition after 48 hrs by broth microdilution test2012Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24
Anti-infective and herbicidal activity of N-substituted 2-aminobenzothiazoles.
AID575099Antimicrobial activity against Streptococcus pneumoniae serotype 15A assessed as percent susceptible isolates by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID132396Efficacy against mouse infected ip with park strain of Streptococcus pneumoniae administered sc to 19-21-g random sex ICR mice at 1 hr and 5 hr1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID25254Pseudo-first-order Rate constant for hydrolysis at pH 101988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
The acylating potential of gamma-lactam antibacterials: base hydrolysis of bicyclic pyrazolidinones.
AID574954Antimicrobial activity against multiple drug resistant Streptococcus pneumoniae serotype 19A by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID23109Mean plasma levels in rats 3h after intravenous administration of 20 mg/kg of compound1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID574951Antimicrobial activity against Streptococcus pneumoniae serotype 7F by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID1209736Inhibition of human OAT3 expressed in CHO cells assessed as inhibition of fluorescein uptake at 500 uM over 20 mins relative to untreated-control2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
AID94128In vitro minimal inhibitory concentration in brain-heart infusion broth in the presence of hog liver esterase(1:1.5) in Klebsiella pneumoniae 0791990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporins to carbapenems: 1-oxygenated carbapenems and carbapenams.
AID1067502Inhibition of Bacillus subtilis 168 PBP2 after 30 mins by SDS-PAGE2014ACS medicinal chemistry letters, Feb-13, Volume: 5, Issue:2
Neutral β-Lactams Inactivate High Molecular Mass Penicillin-Binding Proteins of Class B1, Including PBP2a of MRSA.
AID205886Minimum inhibitory concentration against Epil strain of Staphylococcus epidermidis1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID574949Antimicrobial activity against Streptococcus pneumoniae serotype 3 by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID238858Binding affinity against membrane transport protein PEPT1 in human Caco-2 cells2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1.
AID528533Antimicrobial activity against penicillin-resistant Streptococcus agalactiae B502 by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID557208Antibacterial activity against Beta-lactamase-negative Neisseria meningitidis by Etest method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Antibiotic susceptibility and characteristics of Neisseria meningitidis isolates from the African meningitis belt, 2000 to 2006: phenotypic and genotypic perspectives.
AID574952Antimicrobial activity against Streptococcus pneumoniae serotype 11A by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID717783Antimicrobial activity against methicillin-resistant Staphylococcus aureus H 5996/08 after 24 hrs by broth microdilution method2012Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24
Contribution to investigation of antimicrobial activity of styrylquinolines.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID575084Antimicrobial activity against multiple drug resistant Streptococcus pneumoniae serotype 6B assessed as percent susceptible isolates by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID132393Efficacy against mouse infected ip with C203 strain of Streptococcus pyogenes, administered po to 19-21-g random sex ICR mice at 1 hr and 5 hr1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID22548Half-life calculated from the beta-phase (terminal phase) of the mean intravenous plasma curve1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID528525Antimicrobial activity against penicillin-resistant Streptococcus agalactiae B6 by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID133269Efficacy against mouse infections caused by Streptococcus pyogenes measured as Minimum inhibitory concentration1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 2. Expanded structure-activity relationships of 7-(arylacetamido)-3-substituted cephalosporins.
AID528534Antimicrobial activity against penicillin-resistant Streptococcus agalactiae B503 by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID66739In vitro minimal inhibitory concentration in brain-heart infusion broth in the presence of hog liver esterase(1:1.5) in Enterococcus cloacae 0091990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporins to carbapenems: 1-oxygenated carbapenems and carbapenams.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID523273Antimicrobial activity against Escherichia coli HN1157/pHSG576oxa72010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Kinetic parameters of efflux of penicillins by the multidrug efflux transporter AcrAB-TolC of Escherichia coli.
AID205196In vitro minimal inhibitory concentration (MIC) in brain-heart infusion broth in the presence of hog liver esterase(1:1.5) in Serr. marc. 0951990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporins to carbapenems: 1-oxygenated carbapenems and carbapenams.
AID337693Antibacterial activity against Escherichia coli ATCC 25922 after 48 hrs by silica gel plate-based INT-formazan method
AID557210Antibacterial activity against Beta-lactamase-negative Neisseria meningitidis assessed as percent intermediate isolates by Etest method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Antibiotic susceptibility and characteristics of Neisseria meningitidis isolates from the African meningitis belt, 2000 to 2006: phenotypic and genotypic perspectives.
AID719021Antibacterial activity against Staphylococcus epidermidis H 6996/08 assessed as growth inhibition after 48 hrs by broth microdilution test2012Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24
Anti-infective and herbicidal activity of N-substituted 2-aminobenzothiazoles.
AID1067499Inhibition of Bacillus subtilis 168 PBP5 after 30 mins by SDS-PAGE2014ACS medicinal chemistry letters, Feb-13, Volume: 5, Issue:2
Neutral β-Lactams Inactivate High Molecular Mass Penicillin-Binding Proteins of Class B1, Including PBP2a of MRSA.
AID1067498Inhibition of Staphylococcus aureus PBP2a2014ACS medicinal chemistry letters, Feb-13, Volume: 5, Issue:2
Neutral β-Lactams Inactivate High Molecular Mass Penicillin-Binding Proteins of Class B1, Including PBP2a of MRSA.
AID163776In vitro minimal inhibitory concentration (MIC) in brain-heart infusion broth in the presence of hog liver esterase(1:1.5) in Pseudomonas aeruginosa 1041990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporins to carbapenems: 1-oxygenated carbapenems and carbapenams.
AID232577Ratio of ED50 value evaluated in Staphylococcus aureus by po to sc administration1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 2. Expanded structure-activity relationships of 7-(arylacetamido)-3-substituted cephalosporins.
AID64044In vitro minimal inhibitory concentration (MIC) in brain-heart infusion broth in the presence of hog liver esterase(1:1.5) in Escherichia coli 1291990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporins to carbapenems: 1-oxygenated carbapenems and carbapenams.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID245270Minimum inhibitory concentration against gram negative Klebsiella aerogenes (MTCC 39) using broth dilution method2005Bioorganic & medicinal chemistry letters, Sep-01, Volume: 15, Issue:17
Synthesis and in vitro study of novel 7-O-acyl derivatives of Oroxylin A as antibacterial agents.
AID574953Antimicrobial activity against Streptococcus pneumoniae serotype 6C by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID232579Ratio of ED50 value evaluated in Streptococcus pyogenes by po to sc administration1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 2. Expanded structure-activity relationships of 7-(arylacetamido)-3-substituted cephalosporins.
AID228987Minimum inhibitory concentration against sens CL strain of Haemophilus influenzae1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID603953In-vivo plasma to lung partition coefficients of the compound, logP(lung) in rat2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
AID557209Antibacterial activity against Beta-lactamase-negative Neisseria meningitidis assessed as percent susceptible isolates by Etest method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Antibiotic susceptibility and characteristics of Neisseria meningitidis isolates from the African meningitis belt, 2000 to 2006: phenotypic and genotypic perspectives.
AID557394Antibacterial activity against Beta-lactamase-negative Neisseria meningitidis assessed as percent resistant isolates by Etest method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Antibiotic susceptibility and characteristics of Neisseria meningitidis isolates from the African meningitis belt, 2000 to 2006: phenotypic and genotypic perspectives.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID131378Effective dose administered orally (po) to 19-21-g random sex ICR mice at 1 hr and 5 hr intervals after intraperitoneal Streptococcus pneumoniae1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 2. Expanded structure-activity relationships of 7-(arylacetamido)-3-substituted cephalosporins.
AID10707Area under plasma concentration vs time curve observed in female mongrel dogs after, oral administration of single 15 mg/kg dose1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID523270Permeability across Escherichia coli HN1157/pHSG576oxa7 assessed as permeability coefficient in presence of proton uncoupler carbonyl cyanide meta-chlorophenylhydrazone2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Kinetic parameters of efflux of penicillins by the multidrug efflux transporter AcrAB-TolC of Escherichia coli.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID131504Effective dose administered subcutaneously (sc) to 19-21-g random sex ICR mice at 1 hr and 5 hr intervals after intraperitoneal administration of Staphylococcus aureus1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 2. Expanded structure-activity relationships of 7-(arylacetamido)-3-substituted cephalosporins.
AID25950Half-life of the compound1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID574950Antimicrobial activity against Streptococcus pneumoniae serotype 35B by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID574948Antimicrobial activity against Streptococcus pneumoniae serotype 19A by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID10706Area under plasma concentration vs time curve observed in female mongrel dogs after, iv administration of single 15 mg/kg dose1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID93878Minimum inhibitory concentration against X68 strain of Klebsiella pneumoniae1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID717780Antimicrobial activity against Staphylococcus epidermidis H 6966/08 after 48 hrs by broth microdilution method2012Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24
Contribution to investigation of antimicrobial activity of styrylquinolines.
AID19520Half-life of compound in acetate buffer (pH 4.5)1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Coupling products of amino acids to penicillin V and cephalothin: synthesis and susceptibility to carboxypeptidases and lysosomal enzymes.
AID1209734Inhibition of mouse OAT1 expressed in CHO cells assessed as inhibition of fluorescein uptake at 500 uM over 20 mins relative to untreated-control2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
AID1209732Drug uptake by mouse OAT3 expressed in CHO cells at 100 uM after 25 mins by HPLC/UV detection method in presence of probenecid2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID575102Antimicrobial activity against Streptococcus pneumoniae serotype 19F assessed as percent susceptible isolates by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID717785Antimicrobial activity against Staphylococcus aureus CCM 4516/08 after 24 hrs by broth microdilution method2012Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24
Contribution to investigation of antimicrobial activity of styrylquinolines.
AID1067501Inhibition of Bacillus subtilis 168 PBP3 after 30 mins by SDS-PAGE2014ACS medicinal chemistry letters, Feb-13, Volume: 5, Issue:2
Neutral β-Lactams Inactivate High Molecular Mass Penicillin-Binding Proteins of Class B1, Including PBP2a of MRSA.
AID52920In vitro minimal inhibitory concentration (MIC) in brain-heart infusion broth in the presence of hog liver esterase(1:1.5) in Citrobacter diversus 0311990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporins to carbapenems: 1-oxygenated carbapenems and carbapenams.
AID205885Minimum inhibitory concentration against 222 strain of Staphylococcus epidermidis1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID144367Minimum inhibitory concentration against N9 strain of Shigella sonnei1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID523272Antimicrobial activity against Escherichia coli HN1157/pHSG576oxa7 assessed as minimal drug concentration2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Kinetic parameters of efflux of penicillins by the multidrug efflux transporter AcrAB-TolC of Escherichia coli.
AID13851Bioavailability in rat1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID717784Antimicrobial activity against Staphylococcus aureus CCM 4516/08 after 48 hrs by broth microdilution method2012Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24
Contribution to investigation of antimicrobial activity of styrylquinolines.
AID200256In vitro minimal inhibitory concentration (MIC) in brain-heart infusion broth in the presence of hog liver esterase(1:1.5) in Staphylococcus aureus 4001990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporins to carbapenems: 1-oxygenated carbapenems and carbapenams.
AID23126Maximum bioavailability in individual rat; range is 4-341988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID14028Oral bioavailability in Rhesus monkey1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID719023Antibacterial activity against Staphylococcus epidermidis H 6996/08 assessed as growth inhibition after 24 hrs by broth microdilution test2012Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24
Anti-infective and herbicidal activity of N-substituted 2-aminobenzothiazoles.
AID528527Antimicrobial activity against penicillin-resistant Streptococcus agalactiae B8 by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID133286Minimum inhibitory concentration against mouse infected with C203 strain of Streptococcus pyogenes1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID337692Antibacterial activity against Bacillus subtilis ATCC 6633 after 48 hrs by silica gel plate-based INT-formazan method
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID200255In vitro minimal inhibitory concentration (MIC) in brain-heart infusion broth in the presence of hog liver esterase(1:1.5) in Staphylococcus aureus 0051990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporins to carbapenems: 1-oxygenated carbapenems and carbapenams.
AID781325pKa (acid-base dissociation constant) as determined by Liao ref: J Chem Info Model 20092014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID79397In vitro minimal inhibitory concentration (MIC) in brain-heart infusion broth in the presence of hog liver esterase(1:1.5) in Haemophilus influenzae 1021990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporins to carbapenems: 1-oxygenated carbapenems and carbapenams.
AID1067494Antimicrobial activity against Bacillus licheniformis NRS 1264 after 18 hrs by serial dilution method2014ACS medicinal chemistry letters, Feb-13, Volume: 5, Issue:2
Neutral β-Lactams Inactivate High Molecular Mass Penicillin-Binding Proteins of Class B1, Including PBP2a of MRSA.
AID1209735Inhibition of mouse OAT3 expressed in CHO cells assessed as inhibition of fluorescein uptake at 500 uM over 20 mins relative to untreated-control2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
AID717782Antimicrobial activity against methicillin-resistant Staphylococcus aureus H 5996/08 after 48 hrs by broth microdilution method2012Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24
Contribution to investigation of antimicrobial activity of styrylquinolines.
AID575082Antimicrobial activity against multiple drug resistant Streptococcus pneumoniae serotype 19A assessed as percent susceptible isolates by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID103831In vitro minimal inhibitory concentration (MIC) in brain-heart infusion broth in the presence of hog liver esterase(1:1.5) in Morganella morganii 0011990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporins to carbapenems: 1-oxygenated carbapenems and carbapenams.
AID131379Effective dose administered orally (po) to 19-21-g random sex ICR mice at 1 hr and 5 hr intervals after intraperitoneal Staphylococcus aureus1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 2. Expanded structure-activity relationships of 7-(arylacetamido)-3-substituted cephalosporins.
AID133288Minimum inhibitory concentration against mouse infected with park strain of Streptococcus pneumoniae1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID1067495Antimicrobial activity against wild type Staphylococcus epidermidis ATCC 12228 after 18 hrs by serial dilution method2014ACS medicinal chemistry letters, Feb-13, Volume: 5, Issue:2
Neutral β-Lactams Inactivate High Molecular Mass Penicillin-Binding Proteins of Class B1, Including PBP2a of MRSA.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1067497Antimicrobial activity against wild type Escherichia coli MM 294 after 18 hrs by serial dilution method2014ACS medicinal chemistry letters, Feb-13, Volume: 5, Issue:2
Neutral β-Lactams Inactivate High Molecular Mass Penicillin-Binding Proteins of Class B1, Including PBP2a of MRSA.
AID67851Minimum inhibitory concentration against EB17 strain of Enterobacter aerogenes1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID528739Antimicrobial activity against penicillin-resistant Streptococcus agalactiae B516 by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID719025Antibacterial activity against methicillin-resistant Staphylococcus aureus H 5996/08 assessed as growth inhibition after 24 hrs by broth microdilution test2012Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24
Anti-infective and herbicidal activity of N-substituted 2-aminobenzothiazoles.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID575077Antimicrobial activity against Streptococcus pneumoniae serotype 3 assessed as percent susceptible isolates by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID245279Minimum inhibitory concentration against gram positive Staphylococcus aureus (MTCC 96) using broth dilution method2005Bioorganic & medicinal chemistry letters, Sep-01, Volume: 15, Issue:17
Synthesis and in vitro study of novel 7-O-acyl derivatives of Oroxylin A as antibacterial agents.
AID523266Activity at Escherichia coli isolate 7181 beta-lactamase OXA-72010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Kinetic parameters of efflux of penicillins by the multidrug efflux transporter AcrAB-TolC of Escherichia coli.
AID1067506Inhibition of Escherichia coli PBP3 after 30 mins by SDS-PAGE2014ACS medicinal chemistry letters, Feb-13, Volume: 5, Issue:2
Neutral β-Lactams Inactivate High Molecular Mass Penicillin-Binding Proteins of Class B1, Including PBP2a of MRSA.
AID575081Antimicrobial activity against Streptococcus pneumoniae serotype 6C assessed as percent susceptible isolates by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID1067500Inhibition of Bacillus subtilis 168 PBP4 after 30 mins by SDS-PAGE2014ACS medicinal chemistry letters, Feb-13, Volume: 5, Issue:2
Neutral β-Lactams Inactivate High Molecular Mass Penicillin-Binding Proteins of Class B1, Including PBP2a of MRSA.
AID528524Antimicrobial activity against penicillin-resistant Streptococcus agalactiae B1 by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID19521Half-life of compound in the presence of lysosomal enzymes in the acetate buffer1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Coupling products of amino acids to penicillin V and cephalothin: synthesis and susceptibility to carboxypeptidases and lysosomal enzymes.
AID132395Efficacy against mouse infected ip with park strain of Streptococcus pneumoniae administered po to 19-21-g random sex ICR mice at 1 hr and 5 hr1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID575080Antimicrobial activity against Streptococcus pneumoniae serotype 11A assessed as percent susceptible isolates by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID13843Oral bioavailability in mouse1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID131505Effective dose administered subcutaneously (sc) to 19-21-g random sex ICR mice at 1 hr and 5 hr intervals after intraperitoneal administration of Streptococcus pyogenes1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 2. Expanded structure-activity relationships of 7-(arylacetamido)-3-substituted cephalosporins.
AID1067496Antimicrobial activity against wild type Bacillus subtilis 168 after 18 hrs by serial dilution method2014ACS medicinal chemistry letters, Feb-13, Volume: 5, Issue:2
Neutral β-Lactams Inactivate High Molecular Mass Penicillin-Binding Proteins of Class B1, Including PBP2a of MRSA.
AID10708Area under plasma concentration vs time curve observed in rats for 0-3 h1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID528741Antimicrobial activity against penicillin-resistant Streptococcus agalactiae ATCC BAA-611 harboring PBP-2X V405A mutant gene by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID523271Lipophilicity, log P of the compound2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Kinetic parameters of efflux of penicillins by the multidrug efflux transporter AcrAB-TolC of Escherichia coli.
AID207833Minimum inhibitory concentration against X1.1 strain of Staphylococcus aureus1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID23110Mean plasma levels in rats 40 min after iv administration of 100 mg/kg of probenecid 5 min prior to test compound1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID69199Minimum inhibitory concentration against EC14 strain Escherichia coli1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID10704Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID22647dose in urine (24-h urine excretion) in female mongrel dogs after, oral administration of single 15 mg/kg dose1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID94126In vitro minimal inhibitory concentration (MIC) in brain-heart infusion broth in the presence of hog liver esterase(1:1.5) in Klebsiella pneumoniae 0091990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporins to carbapenems: 1-oxygenated carbapenems and carbapenams.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID575100Antimicrobial activity against Streptococcus pneumoniae serotype 22F assessed as percent susceptible isolates by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID207822Minimum inhibitory concentration against S13E strain of Staphylococcus aureus1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID23111Mean plasma levels in rats at a time 5 min after iv administration of 100 mg/kg of probenecid 5 min prior to test compound1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID523268Activity at Escherichia coli isolate HN1157 AcrAB-TolC efflux transporter2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Kinetic parameters of efflux of penicillins by the multidrug efflux transporter AcrAB-TolC of Escherichia coli.
AID133271Efficacy against mouse infections caused by S. Pneumoniae opmeasured as Minimum inhibitory concentration1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 2. Expanded structure-activity relationships of 7-(arylacetamido)-3-substituted cephalosporins.
AID528526Antimicrobial activity against penicillin-resistant Streptococcus agalactiae B7 by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID523269Binding affinity to Escherichia coli isolate HN1157 AcrAB-TolC efflux transporter2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Kinetic parameters of efflux of penicillins by the multidrug efflux transporter AcrAB-TolC of Escherichia coli.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1910632Inhibition of recombinant SARS-CoV-2 Main protease using ALNDFSNSGSDVLYQPPQTSITSAVLQ/SGFRKMAFPS-NH2 as substrate preincubated for 45 to 75 mins followed by substrate addition measured after 6 mins by SPE-MS inhibition assay2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Penicillin Derivatives Inhibit the SARS-CoV-2 Main Protease by Reaction with Its Nucleophilic Cysteine.
AID207832Minimum inhibitory concentration against V41 strain of Staphylococcus aureus1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID572487Antimicrobial activity against multiple drug resistant Streptococcus pneumoniae ATCC 700677 infected in po dosed BALB/c mouse administered twice daily for 3 days2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID528529Antimicrobial activity against penicillin-resistant Streptococcus agalactiae B12 by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID23324Percent of urinary recovery in rats after, oral administration of single 20 mg/kg dose in solution (N,range)1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID528740Antimicrobial activity against penicillin-resistant Streptococcus agalactiae ATCC BAA-611 harboring PBP-2X Q557E mutant gene by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID1067505Inhibition of Escherichia coli PBP4 after 30 mins by SDS-PAGE2014ACS medicinal chemistry letters, Feb-13, Volume: 5, Issue:2
Neutral β-Lactams Inactivate High Molecular Mass Penicillin-Binding Proteins of Class B1, Including PBP2a of MRSA.
AID10705Area under plasma concentration vs time curve observed in Rhesus monkeys after oral administration of single 30 mg/kg dose1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID23108Mean plasma levels in rats 2 hr after iv administration of 100 mg/kg of probenecid 5 min prior to test compound1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID91481Binding constant against human serum albumin (HSA)2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
Cheminformatic models to predict binding affinities to human serum albumin.
AID200340Minimum inhibitory concentration against X514 strain of Salmonella1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID1209731Drug uptake by mouse OAT3 expressed in CHO cells at 100 uM after 25 mins by HPLC/UV detection method2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
AID14029Oral bioavailability in dog (female mongrel)1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID560133Ratio of Kcat to Km for recombinant beta-lactamase RTG4 expressed in Escherichia coli TOP10 by nitrocefin hydrolysis assay2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii.
AID528531Antimicrobial activity against penicillin-resistant Streptococcus agalactiae B60 by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID209641Minimum inhibitory concentration against Streptococcus pyogenes C2031988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID228412Minimum inhibitory concentration against res 76 strain of Haemophilus influenzae1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1067504Inhibition of Bacillus subtilis 168 PBP1 after 30 mins by SDS-PAGE2014ACS medicinal chemistry letters, Feb-13, Volume: 5, Issue:2
Neutral β-Lactams Inactivate High Molecular Mass Penicillin-Binding Proteins of Class B1, Including PBP2a of MRSA.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID528532Antimicrobial activity against penicillin-resistant Streptococcus agalactiae B68 by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID131503Effective dose administered subcutaneously (sc) to 19-21-g random sex ICR mice at 1 hr and 5 hr intervals after intraperitoneal administration of Streptococcus pneumoniae1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 2. Expanded structure-activity relationships of 7-(arylacetamido)-3-substituted cephalosporins.
AID1209730Inhibition of mouse OAT3 expressed in CHO cells assessed as inhibition of fluorescein uptake over 20 mins2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
AID209617In vitro minimal inhibitory concentration (MIC) in brain-heart infusion broth in the presence of hog liver esterase(1:1.5) in Streptococcus pyogenes 2031990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporins to carbapenems: 1-oxygenated carbapenems and carbapenams.
AID528523Antimicrobial activity against penicillin-resistant Streptococcus agalactiae ATCC 12403 by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID575076Antimicrobial activity against Streptococcus pneumoniae serotype 19A assessed as percent susceptible isolates by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID528536Antimicrobial activity against penicillin-resistant Streptococcus agalactiae B514 by agar dilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
First molecular characterization of group B streptococci with reduced penicillin susceptibility.
AID245264Minimum inhibitory concentration against gram positive Bacillus sphaericus (MTCC 11) using broth dilution method2005Bioorganic & medicinal chemistry letters, Sep-01, Volume: 15, Issue:17
Synthesis and in vitro study of novel 7-O-acyl derivatives of Oroxylin A as antibacterial agents.
AID575083Antimicrobial activity against multiple drug resistant Streptococcus pneumoniae serotype 19F assessed as percent susceptible isolates by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID1067503Inhibition of Escherichia coli PBP5/6 after 30 mins by SDS-PAGE2014ACS medicinal chemistry letters, Feb-13, Volume: 5, Issue:2
Neutral β-Lactams Inactivate High Molecular Mass Penicillin-Binding Proteins of Class B1, Including PBP2a of MRSA.
AID133285Minimum inhibitory concentration against mouse infected with 3055 strain of Staphylococcus aureus1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID22552Half-life calculated from the beta-phase (terminal phase) of the mean intravenous plasma curve in Rhesus monkeys1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID717781Antimicrobial activity against Staphylococcus epidermidis H 6966/08 after 24 hrs by broth microdilution method2012Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24
Contribution to investigation of antimicrobial activity of styrylquinolines.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID23325Percent of urinary recovery in rats after, sc administration of single 20 mg/kg dose in solution (N,range)1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID449704NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID681171TP_TRANSPORTER: inhibition of TEA uptake in Xenopus laevis oocytes1997DNA and cell biology, Jul, Volume: 16, Issue:7
Cloning and characterization of two human polyspecific organic cation transporters.
AID540067Inhibition of human recombinant NQO22010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2).
AID449706NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested.2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID681157TP_TRANSPORTER: inhibition of TEA uptake in Xenopus laevis oocytes1994Nature, Dec-08, Volume: 372, Issue:6506
Drug excretion mediated by a new prototype of polyspecific transporter.
AID681560TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 0.25 uM) in OCT1-expressing HEK293 cells2002British journal of pharmacology, Jul, Volume: 136, Issue:6
Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3.
AID449703NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay 2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID681376TP_TRANSPORTER: inhibition of MPP+ uptake in OCT1-expressing HEK293 cells
AID679498TP_TRANSPORTER: inhibition of MPP+ uptake in Xenopus laevis oocytes1997Molecular pharmacology, Jun, Volume: 51, Issue:6
Cloning and functional expression of a human liver organic cation transporter.
AID678970TP_TRANSPORTER: inhibition of TEA uptake (TEA: 100 uM) in Xenopus laevis oocytes1999Biochimica et biophysica acta, Mar-04, Volume: 1417, Issue:2
Molecular mechanisms of organic cation transport in OCT2-expressing Xenopus oocytes.
AID449705NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID681146TP_TRANSPORTER: inhibition of TEA uptake in OCT1-expressing HeLa cells1998The Journal of pharmacology and experimental therapeutics, Jul, Volume: 286, Issue:1
Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa).
AID681561TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 0.25 uM) in OCT2-expressing HEK293 cells2002British journal of pharmacology, Jul, Volume: 136, Issue:6
Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3.
AID682144TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 0.25 uM) in OCT3-expressing HEK293 cells2002British journal of pharmacology, Jul, Volume: 136, Issue:6
Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3.
AID540069Inhibition of human recombinant NQO2 at 100 uM2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2).
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,029)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901371 (67.57)18.7374
1990's309 (15.23)18.2507
2000's195 (9.61)29.6817
2010's127 (6.26)24.3611
2020's27 (1.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 95.18

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index95.18 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.30 (4.65)
Search Engine Demand Index164.56 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (95.18)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials330 (14.99%)5.53%
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews94 (4.27%)6.00%
Reviews0 (0.00%)6.00%
Reviews0 (0.00%)6.00%
Case Studies205 (9.31%)4.05%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational4 (0.18%)0.25%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other1,568 (71.24%)84.16%
Other9 (100.00%)84.16%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (17)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics [NCT02099240]Early Phase 111 participants (Actual)Interventional2014-03-06Terminated(stopped due to Not enough patient enrollment and lack of staffing)
Tick Borne Diseases in Norwegian General Practice. A Randomized, Controlled Trial for Treatment of Erythema Migrans in Norwegian General Practice. A Comparison of Phenoxymethylpenicillin, Amoxicillin and Doxycycline. [NCT01368341]Phase 4225 participants (Anticipated)Interventional2011-06-30Completed
PENTRIOX - a Randomized, Placebo-controlled Clinical Study on the Possible Induction of Oxidative Stress by Phenoxymethylpenicillin and Trimethoprim on Healthy Volunteers [NCT02188472]Phase 190 participants (Actual)Interventional2010-11-30Completed
Does Oral Penicillin Reach and Simulate Intravenous Penicillin Levels in Venous Umbilical Cord Blood of Laboring Pregnant Patients? [NCT00823433]Early Phase 125 participants (Actual)Interventional2009-01-31Terminated(stopped due to Insufficient enrollment.)
Effects of Phenoximethylpenicillin, Amoxicillin and Amoxicillin-clavulanic Acid on the Gut Microbiota of Healthy Volunteers: a Randomized Clinical Trail [NCT04084106]Phase 4104 participants (Actual)Interventional2019-09-10Completed
Peritonsillar Abscess: Aspiration Versus Tonsillectomy a Chaud [NCT03326661]128 participants (Anticipated)Interventional2017-11-10Not yet recruiting
A Randomized Controlled Clinical Trial of Streptococcus Group A-negative Acute Tonsillitis in Primary Health Care - a Comparison of Phenoxymethylpenicillin and no Antibiotic Treatment [NCT04083417]Phase 4260 participants (Anticipated)Interventional2019-09-09Recruiting
A Randomized Controlled Study of 5 and 10 Days Treatment With Phenoxymethylpenicillin for Pharyngotonsillitis Caused by Streptococcus Group A [NCT02712307]Phase 4433 participants (Actual)Interventional2015-09-30Completed
Microneedle Sensing of Beta-lactam Antibiotic Concentrations in Human Interstitial Fluid [NCT03847610]Phase 111 participants (Actual)Interventional2018-04-12Completed
Intravenous Immunoglobulins as Effective Treatment in Sydenham's Chorea [NCT00615797]20 participants (Actual)Interventional2002-05-31Completed
Oral Flucloxacillin Alone Versus Flucloxacillin and Phenoxymethylpenicillin for the Emergency Department Outpatient Treatment of Cellulitis: a Non-inferiority Randomised Controlled Trial. [NCT02922686]Phase 4414 participants (Anticipated)Interventional2016-12-31Not yet recruiting
Randomised Controlled Trial to Investigate Whether Prophylactic Antibiotics Can Prevent Further Episodes of Cellulitis (Erysipelas) of the Leg (PATCH I) [NCT00552799]Phase 4274 participants (Actual)Interventional2006-07-31Completed
A Pharmacokinetic and Pharmacodynamic Study of Phenoxymethylpenicillin for Children [NCT01499875]Phase 180 participants (Actual)Interventional2012-01-31Completed
Intramuscular vs. Enteral Penicillin Prophylaxis to Prevent Progression of Latent Rheumatic Heart Disease: A Non-inferiority Randomized Trial [NCT05693545]Phase 21,004 participants (Anticipated)Interventional2023-09-01Recruiting
Efficacy of High Doses of Oral Penicillin V Versus High Doses of Oral Amoxicillin in the Treatment of Non-severe Community-acquired Pneumonia in Adults [NCT03208361]Phase 343 participants (Actual)Interventional2013-11-05Terminated(stopped due to Lack of financial support to continue with the study recruitment. Independent study financially supported by a national grant with a 4.5 years duration.)
Surgical Treatment of Peri-implantitis With and Without Systemically Adjunctive Antibiotics A Prospective, Double Blind, Randomized, Three Armed, Parallel, Placebo Controlled Clinical Trial [NCT02185209]Phase 477 participants (Actual)Interventional2015-03-31Completed
The Effects of Zinc Supplementation in Children With Sickle Cell Disease in Western Kenya: a Pilot Study [NCT03293641]40 participants (Actual)Interventional2016-05-20Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT03847610 (1) [back to overview]Assessment of the Biosensors Ability to Track Phenoxymethylpenicillin Concentrations Compared to Observations Made by Microdialysis and Blood Sampling

Assessment of the Biosensors Ability to Track Phenoxymethylpenicillin Concentrations Compared to Observations Made by Microdialysis and Blood Sampling

Bland-Altman plot to describe agreement between interstitial phenoxymethylpenicillin concentrations and microneedle data (mean difference between microneedle and microdialysis measurements) (NCT03847610)
Timeframe: Up to 12 hours

Interventionmg/L (Mean)
Healthy Volunteer-0.16

[back to top]